Therefore, our study revealed an RGS19/MYH9/β-catenin/c-Myc regulatory circuit in HCC, supporting RGS19 as a novel diagnostic marker and treatment target in patients with HCC. This evidence concerns the gene MYC and hepatocellular carcinoma.